ETF Holdings Breakdown of RNA

RNA institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	28,576	USD 1,368,505
2025-10-17	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	81,492	USD 3,902,652
2025-10-17	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	81,492	USD 3,902,652
2025-10-17	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	74,192	USD 3,553,055
2025-10-17	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	499	USD 23,897
Total =		266,251	USD 12,750,761

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with RNA

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at Roth Capital

Roth Capital started coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report released on Wednesday, Marketbeat.com reports. The brokerage issued a buy rating and a $62.00 price objective on the biotechnology company’s stock. A number of other equities analysts also recently weighed in on the stock. Wolfe Research began coverage on […] - 2025-09-18 04:26:54

Bank of America Raises Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00

Avidity Biosciences (NASDAQ:RNA – Get Free Report) had its target price raised by research analysts at Bank of America from $56.00 to $65.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s price objective suggests a potential upside of 56.85% from […] - 2025-09-17 02:38:42

Brokerages Set Avidity Biosciences, Inc. (NASDAQ:RNA) Price Target at $67.00

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has been assigned a consensus rating of “Buy” from the eighteen ratings firms that are presently covering the firm, Marketbeat.com reports. Seventeen equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 […] - 2025-09-12 02:32:51

Avidity Biosciences (NASDAQ:RNA) Stock Price Down 4.2% After Insider Selling

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report)’s stock price dropped 4.2% on Monday after an insider sold shares in the company. The stock traded as low as $44.55 and last traded at $44.51. Approximately 1,095,468 shares changed hands during trading, a decline of 40% from the average daily volume of 1,834,316 shares. The stock […] - 2025-08-20 02:34:50

Avidity Biosciences (NASDAQ:RNA) Shares Gap Down on Insider Selling

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report)’s stock price gapped down prior to trading on Monday after an insider sold shares in the company. The stock had previously closed at $46.29, but opened at $44.46. Avidity Biosciences shares last traded at $44.45, with a volume of 505,071 shares. Specifically, insider Steven George Hughes sold […] - 2025-08-12 02:18:50

Barclays Increases Avidity Biosciences (NASDAQ:RNA) Price Target to $62.00

Avidity Biosciences (NASDAQ:RNA – Free Report) had its price target boosted by Barclays from $59.00 to $62.00 in a research note released on Friday,Benzinga reports. Barclays currently has an overweight rating on the biotechnology company’s stock. A number of other brokerages also recently commented on RNA. Bank of America lifted their price objective on Avidity […] - 2025-08-11 03:50:56

Oppenheimer Asset Management Inc. Invests $226,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)

Oppenheimer Asset Management Inc. bought a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) during the first quarter, Holdings Channel reports. The fund bought 7,657 shares of the biotechnology company’s stock, valued at approximately $226,000. Several other hedge funds have also modified their holdings of the stock. Parallel Advisors LLC raised […] - 2025-07-01 04:52:51

Avidity Biosciences (NASDAQ:RNA) Now Covered by Sanford C. Bernstein

Investment analysts at Sanford C. Bernstein began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a research note issued to investors on Tuesday, MarketBeat reports. The brokerage set an “outperform” rating and a $50.00 price target on the biotechnology company’s stock. Sanford C. Bernstein’s price target indicates a potential upside of […] - 2025-06-26 02:48:48

Avidity Biosciences (NASDAQ:RNA) Earns Outperform Rating from Analysts at Wolfe Research

Equities research analysts at Wolfe Research assumed coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a research note issued on Tuesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $55.00 price target on the biotechnology company’s stock. Wolfe Research’s price objective points to a potential upside of 87.59% from […] - 2025-06-19 02:42:48

Assenagon Asset Management S.A. Raises Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

Assenagon Asset Management S.A. raised its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 411.3% during the 1st quarter, Holdings Channel reports. The fund owned 207,372 shares of the biotechnology company’s stock after purchasing an additional 166,813 shares during the period. Assenagon Asset Management S.A.’s holdings in Avidity Biosciences were worth […] - 2025-06-15 05:44:49

Chardan Capital Forecasts Strong Price Appreciation for Avidity Biosciences (NASDAQ:RNA) Stock

Avidity Biosciences (NASDAQ:RNA – Get Free Report) had its price objective raised by research analysts at Chardan Capital from $65.00 to $75.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price target would indicate a potential upside of 123.08% from the company’s […] - 2025-06-11 04:58:52

Avidity Biosciences (NASDAQ:RNA) Stock Price Expected to Rise, Bank of America Analyst Says

Avidity Biosciences (NASDAQ:RNA – Get Free Report) had its price objective hoisted by stock analysts at Bank of America from $48.00 to $54.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s price target would indicate a potential upside of 60.62% from […] - 2025-06-11 03:00:54

Avidity Biosciences (NASDAQ:RNA) Shares Gap Up Following Analyst Upgrade

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) shares gapped up before the market opened on Monday after Citigroup raised their price target on the stock from $70.00 to $75.00. The stock had previously closed at $36.24, but opened at $38.00. Citigroup currently has a buy rating on the stock. Avidity Biosciences shares last traded […] - 2025-06-11 02:08:44

Traders Purchase Large Volume of Avidity Biosciences Put Options (NASDAQ:RNA)

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock traders acquired 7,058 put options on the company. This is an increase of 1,411% compared to the typical daily volume of 467 put options. Avidity Biosciences Price Performance Shares of Avidity Biosciences stock opened at […] - 2025-06-06 05:14:54

Brokerages Set Avidity Biosciences, Inc. (NASDAQ:RNA) Price Target at $66.38

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has earned a consensus recommendation of “Buy” from the thirteen research firms that are currently covering the stock, MarketBeat.com reports. Thirteen research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued a report on the stock in […] - 2025-06-04 02:36:49

Nuveen Asset Management LLC Has $10.25 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

Nuveen Asset Management LLC reduced its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 66.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 352,498 shares of the biotechnology company’s stock after selling 706,062 shares during the period. Nuveen Asset Management LLC’s holdings in Avidity Biosciences were worth $10,251,000 at the […] - 2025-05-28 05:52:59

Investors Purchase Large Volume of Put Options on Avidity Biosciences (NASDAQ:RNA)

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) saw some unusual options trading activity on Monday. Stock traders bought 9,017 put options on the company. This represents an increase of 2,083% compared to the typical volume of 413 put options. Analysts Set New Price Targets A number of equities analysts have recently commented on RNA […] - 2025-05-20 02:36:59

Deutsche Bank AG Purchases 30,340 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

Deutsche Bank AG grew its position in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 18.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 193,586 shares of the biotechnology company’s stock after buying an additional 30,340 shares during the period. Deutsche Bank AG owned […] - 2025-05-19 05:06:59

Stifel Financial Corp Reduces Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

Stifel Financial Corp lowered its position in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 13.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,949 shares of the biotechnology company’s stock after selling 1,063 shares during the period. Stifel Financial Corp’s holdings in Avidity Biosciences were worth $202,000 at the end of the […] - 2025-05-16 04:29:05

HC Wainwright Lowers Avidity Biosciences (NASDAQ:RNA) Price Target to $68.00

Avidity Biosciences (NASDAQ:RNA – Get Free Report) had its target price reduced by research analysts at HC Wainwright from $72.00 to $68.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 127.58% […] - 2025-05-14 02:32:45

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC lifted its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 111.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 17,519 shares of the biotechnology company’s stock after buying an additional 9,230 shares during the quarter. Hsbc Holdings PLC’s holdings in Avidity Biosciences were worth $507,000 at the end […] - 2025-05-07 05:00:55

First Trust Advisors LP Buys 45,254 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

First Trust Advisors LP lifted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 110.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 86,395 shares of the biotechnology company’s stock after acquiring an additional 45,254 shares during the period. First Trust Advisors LP […] - 2025-05-05 05:08:59

Envestnet Asset Management Inc. Sells 3,931 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

Envestnet Asset Management Inc. decreased its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 10.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 33,132 shares of the biotechnology company’s stock after selling 3,931 shares during the quarter. Envestnet […] - 2025-05-02 04:24:46

Raymond James Financial Inc. Makes New $5.78 Million Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)

Raymond James Financial Inc. purchased a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 198,907 shares of the biotechnology company’s stock, valued at approximately $5,784,000. Other hedge funds and […] - 2025-04-25 06:43:06

Legal & General Group Plc Has $2.97 Million Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)

Legal & General Group Plc lifted its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 7.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 102,100 shares of the biotechnology company’s stock after purchasing an additional 6,937 shares […] - 2025-04-24 05:06:51

Summit Investment Advisors Inc. Buys 666 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

Summit Investment Advisors Inc. raised its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 6.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,611 shares of the biotechnology company’s stock after purchasing an additional 666 shares during the period. […] - 2025-04-21 04:56:51

Renaissance Technologies LLC Acquires 69,300 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

Renaissance Technologies LLC lifted its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 48.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 211,200 shares of the biotechnology company’s stock after acquiring an additional 69,300 shares during the period. Renaissance […] - 2025-04-20 05:00:56

Alliancebernstein L.P. Decreases Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

Alliancebernstein L.P. decreased its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 25.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,770 shares of the biotechnology company’s stock after selling 42,914 shares during the quarter. Alliancebernstein L.P.’s holdings in Avidity […] - 2025-04-15 04:50:50

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its position in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by 3.6% in the 4th quarter, Holdings Channel reports. The firm owned 450,144 shares of the biotechnology company’s stock after selling 16,941 shares during the period. JPMorgan Chase & Co.’s holdings in Avidity Biosciences were worth $13,090,000 as of its […] - 2025-04-14 05:13:06

Needham & Company LLC Reaffirms “Buy” Rating for Avidity Biosciences (NASDAQ:RNA)

Avidity Biosciences (NASDAQ:RNA – Get Free Report)‘s stock had its “buy” rating restated by Needham & Company LLC in a report released on Wednesday,Benzinga reports. They currently have a $60.00 target price on the biotechnology company’s stock. Needham & Company LLC’s target price would indicate a potential upside of 148.86% from the stock’s current price. […] - 2025-04-11 06:22:53

Back to Listing

Disclaimer